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Objective: Patients with generalized autoimmune dysautonomia may also present with gastroparesis.
Immune dysfunction in such patients can be evaluated using antibodies to glutamic acid decarboxylase
(GAD) and full thickness biopsy of stomach. In this study, we utilize immunotherapy for treatment of
drug and Gastric Electrical Stimulation (GES) resistant gastroparetic patients with evidence of neuroin-
ﬂammation on full thickness gastric biopsy and had positive GAD65 autoantibodies.
Material and methods: We conducted a retrospective chart review of 11 female patients with drug and
device resistant gastroparesis. Patients were treated for a total of 8–12 weeks with either intravenous
immunoglobulin (IVIg), or combined mycophenolate mofetil (MM) and methylprednisolone, or only MM.
Patients were excluded if they had previous side effects from steroid therapy, low scores on dual-energy
X-ray absorptiometry (DEXA) scan results, immune-compromised conditions with infections like
tuberculosis and zoster. Symptoms of nausea, vomiting, abdominal pain, early satiety/anorexia, bloating
and total symptom score (TSS) as reported by the patients were recorded before and after the treatment
at a follow up visit 2 to 16 weeks after initiation of therapy.
Results: Maximum symptom improvement was seen in patients treated with IVIg (67%). 6 patients (55%)
had improvement in vomiting, whereas 5 patients (45%) had improvements in nausea, abdominal pain
and bloating.
Conclusions: Immunomodulatory therapy shows positive outcomes in improving vomiting symptom in
some gastroparetic patients who have coexisting positive autoimmune proﬁles. This preliminary data
suggests the need for further investigations in immunotherapy targeted to patients with gastroparetic
symptoms refractory to approved drug and device therapies.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).r B.V. This is an open access article
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Gastrointestinal motility disorders can be found in the setting
of generalized autoimmune dysautonomia and may present as
gastroparesis [1]. Several antibodies have been associated with
autoimmune disorders presenting with symptoms of gastroparesis
[2]. Antibodies to Glutamic Acid Decarboxylase (GAD) have been
described in Type 1 diabetes mellitus, and anti-GAD65 is the most
studied isoform [3,4]. Antibodies to GAD have also been exten-
sively studied in many other autoimmune disorders like Stiff-
Person Syndrome (SPS) and Dermatomyositis [5,6]. High titers of
GAD antibodies signify autoimmune dysfunction and the use of
immunomodulating drugs may be indicated for symptomatic
patients with these markers. Studies have shown the beneﬁts of
immunomodulatory therapy in such conditions; however, it has
been systematically applied only in SPS [5].under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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thickness biopsy of the stomach. Patients with gastroparesis show
increased CD45 immunoﬂuorescence in the myenteric plexus and
increased CD68 inﬁltration in the muscle layers, signiﬁcant of
increased immune cells and macrophages expression, respectively,
in the stomach [7]. Along with evidence of immune dysfunction,
gastroparetic patients also have decreased number of interstitial
cells of Cajal and decreased nerve ﬁbers [7].
Immunotherapy has been utilized for patients with autonomic
neurological disorders. Using the same concept, immunotherapy
trial has been utilized with good results for evaluation of patients
with presumed autoimmune gastrointestinal dysmotility [8]. In
this study, we utilize immunotherapy for treatment of drug and
GES resistant patients with symptoms of gastroparesis who were
positive for gastric enteral neuroinﬂammation on full thickness
gastric biopsy and had positive GAD65 autoantibodies.2. Methods
2.1. Study design
This is a retrospective case series of patients identiﬁed through
medical chart review. The clinical protocol was reviewed and
approved by the University of Louisville Institutional Review Board.
2.2. Study subjects
We included gastroparetic patients who had sub-optimal
response to medical therapy and/or gastric enteral stimulation
therapy. All patients had evidence of neuroinﬂammation as
deﬁned by positive GAD65 antibodies and presence of inﬂamma-
tory markers on full thickness gastric biopsy. Western blotting
(ANABLOT) was used to identify human auto-antibodies present in
serum with speciﬁcity for a number of antibodies including Scl 70,
Scl 105, SSB 43, Sm 16, Sm 18, and Ku 66. A scaled GI banding score
or GIBS was used to standardize the bands present. All patients
also had evaluation of paraneoplastic antibody panel which
included antineuronal nuclear autoantibody type 1, 2, and 3
(ANNA-1, ANNA-2, ANNA-3), anti-glial nuclear antibody (AGNA),
Purkinje Cell Cytoplasmic Antibody Type-1 (PCA-1), Purkinje Cell
Cytoplasmic Antibody Type-2(PCA-2), Purkinje Cell Cytoplasmic
Antibody Type Tr (PCA-Tr), Amphiphysin Antibody, CRMP-5 anti-
body, Striated Muscle antibody, P/Q-Type Calcium Channel Anti-
body, N-Type Calcium Channel Antibody, ACh Receptor (Muscle)
Binding Antibody, AChR Ganglionic Neuronal Antibody, NeuronalTable 1
Baseline antibody proﬁles of gastroparesis patients selected for immunotherapy treatm
Patient no. Immunotherapy treatment A
1 Mycophenolate mofetil 5
2 Mycophenolate mofetil and Methylprednisolone 5
3 Mycophenolate mofetil and Methylprednisolone 4
4 Mycophenolate mofetil 7
5 Mycophenolate mofetil 2
6 Mycophenolate mofetil and Methylprednisolone 6
7 Mycophenolate mofetil and Methylprednisolone JO
8 Mycophenolate mofetil 7
9 Immunoglobulin JO
10 Immunoglobulin JO
11 Immunoglobulin 4
GAD65: antibodies to glutamic acid decarboxylase, isoform 65.
JO-1: antibodies to cytoplasmic protein, histidyl tRNA.
ANABLOT: western blot for human auto-antibodies including Scl 70, Scl 105, SSB 43, Sm
Paraneoplastic antibodies: ANNA-1, ANNA-2, ANNA-3, AGNA, PCA-1, PCA-2, PCA-Tr, Am
Channel Antibody, N-Type Calcium Channel Antibody, ACh Receptor (Muscle) Binding An(V-G) Kþ Channel Antibody. Patient exclusion criteria included:
previous side effects from steroid therapy, low scores on dual-
energy X-ray absorptiometry (DEXA) bone scan results, immune-
compromised conditions with infections such as tuberculosis and
zoster.3. Methods
All patients in the study received therapy with immunosup-
pressive therapy with either intravenous immunoglobulin, or
mycophenolate mofetil (MMF), or combined daily mycophenolate
mofetil according to the protocol at our center. Intravenous
immunoglobulin or IVIg (this medication is available by a number
of trade names: Carimune NF-BDI Pharma, Columbia, SC; Flebo-
gamma 5% DIF-Grifols, Los Angeles, CA; Gamunex 10%-Talecris,
Durham, NC; Gammagard S/D-Baxter, Deerﬁeld, IL; Octagam 5%-
Octapharma, Toronto, ON) was given weekly for 8–12 weeks.
Mycophenolate Mofetil or MMF (CellCept, Genentech, South San
Francisco, California) was given daily for 12 weeks. Combined
MMF and intravenous or oral methylprednisolone (Medrol, Pﬁzer,
New York, New York) were given daily for 8–12 weeks. Symptoms
of nausea, vomiting, abdominal pain, early satiety/anorexia, and
bloating as reported by the patients on a 5 point scale of 0–4 with
4 being the worst, were recorded before and after the treatment.
Total symptom score (TSS) was calculated by addition of all the
symptom scores. All patients were continued on their medications
for symptomatic management of gastroparesis and had their GES
turned ON. Patients were followed up at clinical visit or by phone
call from 2 to 16 weeks after the initiation of therapy to monitor
the response with ﬁnal determination of therapeutic response
performed after at least 12 weeks of therapy.4. Results
Our clinical series included 11 female gastroparesis patients (10
Caucasians, 1 African-American) with mean of age 45 years. Ten
patients had a history of idiopathic gastroparesis and 1 patient had
diabetic gastroparesis. Three patients were treated with IVIg, four
with combined methylprednisolone and mycophenolate mofetil,
and four with mycophenolate mofetil only (Table 1). ANABLOT
performed on 8 patients showed 7 patients with more than
3 bands each giving them GIBSZ3 (normalo3). Paraneoplastic
antibodies were found in 2 patients. Symptom scores were
recorded in all the 11 patients (Table 2). Among the patients whoent.
NABLOT (no. of bands) Paraneoplastic Antibodies GAD65
Negative Positive
Negative Positive
Negative Positive
Negative Positive
0.03 Positive
Negative Positive
-1–0.6 Negative Positive
Negative Positive
-1–0.3 Negative Positive
-1–1 0.03 Positive
Negative Positive
16, Sm 18, and Ku 66.
phiphysin Antibody, CRMP-5 antibody, Striated Muscle antibody, P/Q-Type Calcium
tibody, AChR Ganglionic Neuronal Antibody, Neuronal (V-G) Kþ Channel Antibody.
Table 2
Patient reported change in symptoms after ﬁnishing immunotherapy (n represents the number of patients in each group).
Symptoms Immunoglobulin therapy (n¼3) MMF Therapy (n¼4) MMFþMethylprednisolone therapy (n¼4)
Improvement No change Worsening Improvement No change Worsening Improvement No Change Worsening
Nausea 2 1 0 2 1 1 1 1 2
Vomiting 1 1 1 3 1 0 2 0 2
Abdominal pain 2 1 0 2 1 1 1 2 1
Anorexia/Early satiety 0 2 1 1 1 1 1 3 0
Bloating 2 1 0 2 1 1 1 1 2
TSS 2 1 0 3 1 0 1 1 2
TSS: Total symptom score.
K. Soota et al. / Results in Immunology 6 (2016) 11–14 13received only IVIg, 1 out of 3 had improved vomiting, 2 of 3 had
improved nausea, abdominal pain, bloating, and TSS. For the
patients who received combined treatment with mycophenolate
mofetil and methylprednisolone, 2 out of 4 patients had
improvement in vomiting, 1 of 2 had improvement in nausea,
bloating and TSS. In the group of patients who received only
mycophenolate mofetil, vomiting improved in 3 of 4 patients;
nausea, abdominal pain and bloating improved in 2 of 4 patients
whereas TSS also improved in 3 of 4 patients. All patients com-
bined together, 6/11 (55%) had improvement in vomiting whereas
5/11 (45%) had improvements in nausea, abdominal pain and
bloating. TSS improved in 6 of 11 (55%) patients. Maximum
improvement was seen in the patients receiving IVIg as 2/3
patients (67%) had improved TSS with largest improvement seen
with symptoms of nausea, abdominal pain and bloating.5. Discussion
This is a pilot study evaluating the role of immunotherapy in
patients with drug and GES device refractory gastroparesis with
evidence of autoimmune dysfunction. In our study we have shown
that treatment with immunotherapy in such patients resulted in
symptom improvement in more than 50% of patients as measured
by TSS. We also showed that maximum beneﬁt is obtained by
utilizing IVIg as the immunomodulatory agent.
Gastroparesis is a complex clinical entity, many aspects of
which still remain unknown requiring further investigations [1].
Most patients have idiopathic (36%), diabetic (29%) or post-
surgical (13%) gastroparesis, however, other causes like auto-
immune, paraneoplastic and neurological, are also present. Med-
ical therapy is limited to prokinetic and anti-emetic drugs to
relieve the gastroparetic symptoms of nausea, vomiting, abdom-
inal pain, early satiety or bloating. Gastric electrical stimulator
(GES) can be used in drug refractory gastroparesis and has been
shown to be an effective treatment for gastroparesis, and intract-
able nausea and vomiting but its effects are limited and many
times inadequate [1,9].
In our study, vomiting was the most improved symptom (in
55% of patients) with nausea, abdominal pain and bloating closely
behind (in 45% patients). Patients receiving IVIg reported the
maximum beneﬁt (in 66% patients). Flanagan et al. recently uti-
lized immune therapy to diagnose autoimmune gastrointestinal
dysmotility, although the same study also mentioned about the
improvement of symptoms in such patients [8]. The same study
utilized IVIg on all their patients (n¼23) of which 17 had favorable
response (73%). Our study had a response rate of 66% which is
similar to the other study. However, there are few important dif-
ferences between the two studies. Along with serological testing,
we also utilized full thickness gastric biopsy and Western blot of
anti-nuclear antibody (ANAblot) proﬁle to deﬁne the presence of
immune dysfunction in the patient necessitating immune therapy.On the other hand, Flanagan et al. conducted autonomic testing on
all of the patients which was not performed in all of the patients in
our study. Both the reports performed similar neural antibody
testing.
It should be noted that despite the diagnosis of immune dys-
function leading to idiopathic gastroparesis in all the patients, only
two-thirds of the patients responded well to the treatment. There
is no clear explanation for this but it deﬁnitely needs to be eval-
uated more in the future so that we can utilize this therapy in
selected patients only to prevent unnecessary exposure to medi-
cations. Also, our study is a retrospective case series with limited
number of patients and does not have a placebo control group to
compare the results; however, the results are encouraging and
suggest that, if appropriately diagnosed, gastroparesis in the set-
ting of immune dysfunction can effectively be managed with
immune therapy.
In conclusion, to our knowledge, this is the ﬁrst report of the
use of immunotherapy for treatment of drug and GES resistant
gastroparesis, when GES was utilized. This pilot study suggests
that this technique should be considered as a part of the arma-
mentarium against gastroparesis. However, to further validate the
potential clinical beneﬁt, we recommend prospective evaluation of
this therapy in randomized controlled and blinded trials.Conﬂicts of interest
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